Pfizer recently recalibrated its evaluation score, a nod to shifting trends in the market and its own financial pulse. The ...

Wall Street analysts predict lower second-quarter profits for Ford, GM and Stellantis due to tariff pressures and slowing sales.

Everything to Know about Macro and Markets The S&P 500 (SPX) and the Nasdaq-100 (NDX) inched down from Thursday’s record highs, though still ...

Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over the past decade.

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

American Express stock has been stable but unspectacular this year, staying in lockstep with the broader market. With ...

Pfizer (PFE) reported mixed first quarter earnings Tuesday, as the company focuses on gaining investor interest in its near-term pipeline amid a volatile macro environment in the markets.

Pfizer reaffirmed its 2025 outlook of $61 to $64 billion in revenue and adjusted earnings per share of $2.80 to $3. StockStory aims to help individual investors beat the market.

On a per-share basis, the New York-based company said it had profit of 52 cents. Earnings, adjusted for amortization costs and restructuring costs, were 92 cents per share.

We think Pfizer’s top line will see growth in the low teens, driven by market share gains for Vyndaqel and Abrysvo.

Pfizer Inc. (NYSE:PFE) currently pays a quarterly dividend of $0.42 per share and has a dividend yield of 5.64%, as of September 18.

With Pfizer’s sales rising in Q2, despite falling sales of Covid-19 products, we think that it may well be the turning point for Pfizer stock .